Northern Trust’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-117,548
| Closed | -$1.74M | – | 4531 |
|
|
2024
Q1 | $1.74M | Buy |
117,548
+639
| +0.5% | +$8.98K | ﹤0.01% | 3040 |
|
|
2023
Q4 | $1.57M | Buy |
116,909
+1,540
| +1% | +$19.5K | ﹤0.01% | 3122 |
|
|
2023
Q3 | $1.42M | Sell |
115,369
-623
| -0.5% | -$7.54K | ﹤0.01% | 3119 |
|
|
2023
Q2 | $1.43M | Buy |
115,992
+88,044
| +315% | +$1.1M | ﹤0.01% | 3207 |
|
|
2023
Q1 | $343K | Buy |
27,948
+2,126
| +8% | +$25K | ﹤0.01% | 3602 |
|
|
2022
Q4 | $296K | Buy |
25,822
+1,842
| +8% | +$15.2K | ﹤0.01% | 3688 |
|
|
2022
Q3 | $90K | Buy |
23,980
+177
| +0.7% | +$817 | ﹤0.01% | 4147 |
|
|
2022
Q2 | $142K | Sell |
23,803
-1,260
| -5% | -$7.11K | ﹤0.01% | 4050 |
|
|
2022
Q1 | $159K | Sell |
25,063
-88
| -0.3% | -$494 | ﹤0.01% | 4207 |
|
|
2021
Q4 | $98K | Hold |
25,151
| – | – | ﹤0.01% | 4433 |
|
|
2021
Q3 | $121K | Sell |
25,151
-6,527
| -21% | -$34K | ﹤0.01% | 4354 |
|
|
2021
Q2 | $203K | Sell |
31,678
-4,535
| -13% | -$29.9K | ﹤0.01% | 4161 |
|
|
2021
Q1 | $228K | Buy |
36,213
+323
| +0.9% | +$2.31K | ﹤0.01% | 4070 |
|
|
2020
Q4 | $247K | Sell |
35,890
-742
| -2% | -$3.66K | ﹤0.01% | 3918 |
|
|
2020
Q3 | $146K | Sell |
36,632
-5,154
| -12% | -$18.9K | ﹤0.01% | 3876 |
|
|
2020
Q2 | $139K | Sell |
41,786
-37,883
| -48% | -$129K | ﹤0.01% | 3847 |
|
|
2020
Q1 | $171K | Sell |
79,669
-132
| -0.2% | -$386 | ﹤0.01% | 3714 |
|
|
2019
Q4 | $251K | Sell |
79,801
-145
| -0.2% | -$581 | ﹤0.01% | 3722 |
|
|
2019
Q3 | $360K | Sell |
79,946
-23,217
| -23% | -$116K | ﹤0.01% | 3619 |
|
|
2019
Q2 | $491K | Buy |
103,163
+151
| +0.1% | +$715 | ﹤0.01% | 3552 |
|
|
2019
Q1 | $563K | Buy |
103,012
+26,222
| +34% | +$121K | ﹤0.01% | 3513 |
|
|
2018
Q4 | $233K | Buy |
76,790
+13,044
| +20% | +$45.2K | ﹤0.01% | 3763 |
|
|
2018
Q3 | $267K | Buy |
63,746
+834
| +1% | +$3.51K | ﹤0.01% | 3789 |
|
|
2018
Q2 | $243K | Sell |
62,912
-139,783
| -69% | -$928K | ﹤0.01% | 3799 |
|
|
2018
Q1 | $1.28M | Buy |
202,695
+12,654
| +7% | +$105K | ﹤0.01% | 3300 |
|
|
2017
Q4 | $1.53M | Buy |
190,041
+1,741
| +0.9% | +$16.2K | ﹤0.01% | 3268 |
|
|
2017
Q3 | $2.15M | Buy |
188,300
+4,213
| +2% | +$44.3K | ﹤0.01% | 3130 |
|
|
2017
Q2 | $1.8M | Buy |
184,087
+3,589
| +2% | +$73.3K | ﹤0.01% | 3227 |
|
|
2017
Q1 | $4.37M | Sell |
180,498
-1,908
| -1% | -$47.7K | ﹤0.01% | 2632 |
|
|
2016
Q4 | $5.86M | Buy |
182,406
+7,804
| +4% | +$333K | ﹤0.01% | 2454 |
|
|
2016
Q3 | $8.72M | Sell |
174,602
-1,658
| -0.9% | -$68.8K | ﹤0.01% | 2167 |
|
|
2016
Q2 | $7.47M | Buy |
176,260
+6,071
| +4% | +$331K | ﹤0.01% | 2210 |
|
|
2016
Q1 | $11.2M | Buy |
170,189
+3,861
| +2% | +$202K | ﹤0.01% | 1893 |
|
|
2015
Q4 | $10.3M | Buy |
166,328
+9,884
| +6% | +$695K | ﹤0.01% | 1991 |
|
|
2015
Q3 | $10.5M | Sell |
156,444
-73
| -0% | -$5.96K | ﹤0.01% | 1969 |
|
|
2015
Q2 | $15.2M | Buy |
156,517
+14,324
| +10% | +$1.36M | ﹤0.01% | 1780 |
|
|
2015
Q1 | $13.3M | Buy |
142,193
+4,228
| +3% | +$360K | ﹤0.01% | 1881 |
|
|
2014
Q4 | $12.3M | Sell |
137,965
-5,672
| -4% | -$413K | ﹤0.01% | 1919 |
|
|
2014
Q3 | $9.92M | Sell |
143,637
-487
| -0.3% | -$26K | ﹤0.01% | 2047 |
|
|
2014
Q2 | $8.27M | Sell |
144,124
-15,965
| -10% | -$811K | ﹤0.01% | 2174 |
|
|
2014
Q1 | $6.35M | Sell |
160,089
-11,648
| -7% | -$498K | ﹤0.01% | 2408 |
|
|
2013
Q4 | $7.2M | Buy |
171,737
+4,764
| +3% | +$138K | ﹤0.01% | 2309 |
|
|
2013
Q3 | $4.98M | Buy |
166,973
+103,561
| +163% | +$3.62M | ﹤0.01% | 2510 |
|
|
2013
Q2 | $3.36M | Buy |
+63,412
| New | +$2.78M | ﹤0.01% | 2670 |
|
Other funds holding MACK
RA
JC
Northern Trust's MACK Position: Q2 2024 in Review
Northern Trust sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 117,548 shares — an estimated $1.74M sold.
Northern Trust first reported a position in MACK in Q2 2013 and held it in 44 quarters. The position peaked at $15.2M in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Northern Trust reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Northern Trust sold 117,548 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $1.74M.
- Northern Trust first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 44 quarters.
- Northern Trust's Merrimack Pharmaceuticals, Inc. position peaked at $15.2M in Q2 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Northern Trust's 13F filing for Q2 2024, filed 14 Aug 2024.